Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal
26/12 13:18
(RTTNews) - Bristol Myers Squibb (BMY) and RayzeBio, Inc. (RYZB) announced Tuesday a definitive merger agreement under which Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of est...